Agios Pharmaceuticals
AGIO Small CapHealthcare · Biotechnology
Mis à jour: Aug 2, 2026, 22:14 UTC
Price Chart
Indicateurs clés
Valuation Analysis
About the Company
Agios Pharmaceuticals en bref
Agios Pharmaceuticals (AGIO) is currently trading at 26,03 € with a market capitalization of 1,6 Md €. The 52-week range spans from 19,28 € to 39,88 €; the current price is 34.7% below the yearly high. Year-over-year revenue growth stands at +259.3%.
💰 Dividende
Agios Pharmaceuticals currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.
📊 Avis des analystes
8 analystes évaluent Agios Pharmaceuticals (AGIO) au consensus : Acheter. L'objectif de cours moyen est de 39,34 €, soit un potentiel de +51.15% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 26,88 € à 63,29 €.
Agios Pharmaceuticals : la thèse d'investissement en détail
Agios Pharmaceuticals (AGIO) operates in the Healthcare — specifically Biotechnology — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.
Le scénario haussier
Top-line momentum is unusually strong with revenue expanding 259.3% year-over-year, a pace that puts the company well above the market average and signals genuine demand traction rather than mere cyclical tailwind. Wall Street consensus sits at Buy with an average price target implying roughly 51.15% upside from current levels — analyst sentiment is firmly constructive.
Le scénario baissier
Short interest sits at 11.26% of float — a meaningful contingent of professionals is positioned for the share to fall, which deserves attention even if their thesis may turn out to be wrong.
À surveiller
- The analyst consensus price target implies 51.15% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.
Thèse d'investissement : forces et faiblesses
- Forte croissance du CA de 259.3% sur un an
- Consensus des analystes : Buy
- Bilan solide avec faible endettement (D/E 3.04)
- –Positions vendeuses élevées (11.26%)
- –Free cash flow négatif
Aperçu technique
The price is in a transition zone relative to the moving averages — no clear signal.
Profil de risque
The data points to relatively defensive market behavior, elevated short interest (11.26%).
Trading Data
Related Stocks in the Same Sector
More Santé stocks
Top peers in the same sector — ranked by market cap.
Where can I buy Agios Pharmaceuticals?
Compare top-rated brokers — low fees, trusted providers, fully regulated.
📊 Plutôt un fonds qu’une action isolée ? Comparatif d’ETF :
Live Market Data
Real-time chart, financials, earnings, analysts, insider trades, events & news
